Treatment of multiple sclerosis with interferon beta in clinical practice: 2-year follow-up data from the South Italy Mobile MRI Project

被引:7
作者
Bonavita, S.
Dinacci, D.
Lavorgna, L.
Savettieri, G.
Quattrone, A.
Livrea, P.
Bresciamorra, V.
Orefice, G.
Paciello, M.
Coniglio, G.
Di Costanzo, A.
Valentino, P.
Patti, F.
Salemi, G.
Simone, I.
Tedeschi, G.
机构
[1] Univ Naples 2, Dept Neurol Sci, I-80138 Naples, Italy
[2] Univ Palermo, Dept Neurol, Palermo, Italy
[3] Univ Catanzaro, Dept Neurol, Catanzaro, Italy
[4] Dept Neurol, Bari, Italy
[5] Univ Naples Federico II, Dept Neurol, Naples, Italy
[6] San Carlo Hosp, Dept Neurol, Potenza, Italy
[7] Catania Univ, Dept Neurol, I-95126 Catania, Italy
关键词
interferon beta; multiple sclerosis; phase IV; odds ratio;
D O I
10.1007/s10072-006-0696-6
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
This follow-up study assessed the 2-year clinical and magnetic resonance imaging (MRI) outcomes of patients with multiple sclerosis (MS) originally enrolled in an MRI study conducted at eight centres in south Italy (the South Italy Mobile MRI Project). Of the,597 MS patients recruited at baseline, 391 returned for the follow-up study. Of these, 363 provided 2-year clinical and MRI follow-up data, and 215 were still undergoing treatment with one of four interferon beta regimens: Avonex, 30 mcg intramuscularly once weekly; Betaferon, 250 mcg subcutaneously (sc) every other day; Rebif 22 mcg sc three times weekly (tiw; Rebif 22); or Rebif 44 mcg sc tiw (Rebif 44). Over the 2-year follow-up period, patients receiving the higher dose of Rebif were more likely to remain free from relapses [odds ratio (OR) = 2.23] and from developing both new T2 (OR = 0.15) and new T1 black hole lesions (OR = 0.22), when compared with patients in the Avonex group. Despite some limitations in the trial design, the results from this follow-up study provide helpful clinical and MRI data on the efficacy of interferon beta regimens in MS patients treated in the clinical setting.
引用
收藏
页码:S365 / S368
页数:4
相关论文
共 10 条
[1]
A comparison of observational studies and randomized, controlled trials. [J].
Benson, K ;
Hartz, AJ .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (25) :1878-1886
[2]
Randomized, controlled trials, observational studies, and the hierarchy of research designs. [J].
Concato, J ;
Shah, N ;
Horwitz, RI .
NEW ENGLAND JOURNAL OF MEDICINE, 2000, 342 (25) :1887-1892
[3]
Every-other-day interferon beta-1b versus once-weekly interferon beta-1a for multiple sclerosis: results of a 2-year prospective randomised multicentre study (INCOMIN) [J].
Durelli, L ;
Verdun, E ;
Barbero, P ;
Bergui, M ;
Versino, E ;
Ghezzi, A ;
Montanari, E ;
Zaffaroni, M .
LANCET, 2002, 359 (9316) :1453-1460
[4]
Francis G, 2001, NEUROLOGY, V56, P1628
[5]
Interferon-β-1a in relapsing-remitting multiple sclerosis:: effect on hypointense lesion volume on T1 weighted images [J].
Gasperini, C ;
Pozzilli, C ;
Bastianello, S ;
Giugni, E ;
Horsfield, MA ;
Koudriavtseva, T ;
Galgani, S ;
Paolillo, A ;
Haggiag, S ;
Millefiorini, E ;
Fieschi, C .
JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 1999, 67 (05) :579-584
[6]
MRI monitoring of MS in clinical trials [J].
Miller, DH .
CLINICAL NEUROLOGY AND NEUROSURGERY, 2002, 104 (03) :236-243
[7]
Randomized, comparative study of interferon β-1a treatment regimens in MS -: The EVIDENCE trial [J].
Panitch, H ;
Goodin, DS ;
Francis, G ;
Chang, P ;
Coyle, PK ;
O'Connor, P ;
Monaghan, E ;
Li, D ;
Weinshenker, B .
NEUROLOGY, 2002, 59 (10) :1496-1506
[8]
Magnetic resonance imaging outcome of new enhancing lesions in relapsing-remitting multiple sclerosis patients treated with interferon β1a [J].
Paolillo, A ;
Bastianello, S ;
Frontoni, M ;
Gasperini, C ;
Giugni, E ;
Ciccarelli, O ;
Luccichenti, G ;
Cannoni, S ;
Pozzilli, C .
JOURNAL OF NEUROLOGY, 1999, 246 (06) :443-448
[9]
A longitudinal study of brain atrophy in relapsing multiple sclerosis [J].
Simon, JH ;
Jacobs, LD ;
Campion, MK ;
Rudick, RA ;
Cookfair, DL ;
Herndon, RM ;
Richert, JR ;
Salazar, AM ;
Fischer, JS ;
Goodkin, DE ;
Simonian, N ;
Lajaunie, M ;
Miller, DE ;
Wende, K ;
Martens-Davidson, A ;
Kinkel, RP ;
Munschauer, FE ;
Brownscheidle, CM .
NEUROLOGY, 1999, 53 (01) :139-148
[10]
Brain atrophy and lesion load in a large population of patients with multiple sclerosis [J].
Tedeschi, G ;
Lavorgna, L ;
Russo, P ;
Prinster, A ;
Dinacci, D ;
Savettieri, G ;
Quattrone, A ;
Livrea, P ;
Messina, C ;
Reggio, A ;
Bresciamorra, V ;
Orefice, G ;
Paciello, M ;
Brunetti, A ;
Coniglio, G ;
Bonavita, S ;
Di Costanzo, A ;
Bellacosa, A ;
Valentino, P ;
Quarantelli, M ;
Patti, F ;
Salemi, G ;
Cammarata, E ;
Simone, IL ;
Salvatore, M ;
Bonavita, V ;
Alfano, B .
NEUROLOGY, 2005, 65 (02) :280-285